Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
RKI-1447 inhibits mammary tumor growth by 87% and on average the mammary tumors from RKI-1447 treated mice are 7
Smiles: CCCCCCC(O)CCCCCCCCCCC(=O)OCCO
It does not inhibit other DUBs or other families of cysteine proteases tested (EC50 > 100 mM)
38 nM and 7 nM for D2 receptor and 5-HT2A
Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer
Ac-IETD-AFC (trifluoroacetate salt) Catalog No.:M33639-C RKI-1447 inhibits mammary tumor growthNavitoclax d8 is the deuterium labeled Navitoclax. Navitoclax (ABT 263) is a potent and orally active Bcl 2 family protein inhibitor that binds to multiple anti apoptotic Bcl 2 family proteins, such as Bcl xL, Bcl 2 and Bcl w, with a Ki of less than 1 nM. Product information Molecular Weight: 843. 68 Formula: C33H39F6N5O14 Smiles:
US$ 297.50
US$ 290.00
US$ 187.50
US$ 120.00
US$ 195.00
US$ 16.00
US$ 200.00
US$ 99.00
US$ 212.50
US$ 120.00